Skip to main content
SpringerLink
Log in

Solid Tumors of Childhood

  • Chapter
Oncology

  • 251 Accesses

Abstract

Cancer in children, as compared with adults, is rare. From 1993 to 2000, the incidence of cancer in children and adolescents aged 0 to 19 years was approximately 160 cases per 1 million.1 Despite the relative rarity of the disease and the progress made in therapy, cancer remains the leading cause of disease-related death in children ages 1 to 19 years2 (Figure 62.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute, 2003.

    Google Scholar 

  2. Munson M, Sutton P. Births, marriages, divorces, and deaths: pro-visional data for 2003. National Vital Statistics Reports 2004;52(22).

    Google Scholar 

  3. Sawada T, Hirayama M, Nakata T, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;2(8397):271–273.

    PubMed  CAS  Google Scholar 

  4. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346(14):1047–1053.

    PubMed  Google Scholar 

  5. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346(14):1041–1046.

    PubMed  Google Scholar 

  6. Kerbl R, Urban CE, Ambros IM, et al. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 2003;21(22):4228–4234.

    PubMed  Google Scholar 

  7. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998;90(14):1039–1071.

    PubMed  CAS  Google Scholar 

  8. Choyke PL, Siegel MJ, Craft AW, Green DM, DeBaun MR. Screening for Wilms tumor in children with Beckwith-W iedemann syndrome or idiopathic hemihypertrophy. Med Pediatr Oncol 1999;32(3):196–200.

    PubMed  CAS  Google Scholar 

  9. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 1994;137(suppl 2):S68–S97.

    PubMed  CAS  Google Scholar 

  10. Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Pediatr Radiol 2002;32(4):232–237; discussion 42–44.

    PubMed  Google Scholar 

  11. Hempelmann LH. Epidemiological studies of leukemia in persons exposed to ionizing radiation. Cancer Res 1960;20:18–27.

    PubMed  CAS  Google Scholar 

  12. Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1977;1(1):61–72.

    PubMed  CAS  Google Scholar 

  13. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004;363(9406):345–351.

    PubMed  Google Scholar 

  14. Skinner J, Mee TJ, Blackwell RP, et al. Exposure to power frequency electric fields and the risk of childhood cancer in the UK. Br J Cancer 2002;87(11):1257–1266.

    PubMed  CAS  Google Scholar 

  15. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer (Phila) 1991;68(3):600–604.

    PubMed  CAS  Google Scholar 

  16. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95(9):2770–2775.

    PubMed  CAS  Google Scholar 

  17. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr 1991;119(5):725–732.

    PubMed  CAS  Google Scholar 

  18. Bottomley SJ, Kassner E. Late effects of childhood cancer therapy. J Pediatr Nurs 2003;18(2):126–133.

    PubMed  Google Scholar 

  19. Lackner H, Benesch M, Schagerl S, Kerbl R, Schwinger W, Urban C. Prospective evaluation of late effects after childhood cancer therapy with a follow-up over 9 years. Eur J Pediatr 2000;159(10):750–758.

    PubMed  CAS  Google Scholar 

  20. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003;290(12):1583–1592.

    PubMed  CAS  Google Scholar 

  21. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer (Phila) 1986;57(9):1887–1893.

    PubMed  CAS  Google Scholar 

  22. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984;81(15):4940–4944.

    PubMed  CAS  Google Scholar 

  23. Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet 1986;19(1–2):101–111.

    PubMed  CAS  Google Scholar 

  24. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16(11):2985–2995.

    PubMed  CAS  Google Scholar 

  25. Brodeur GM, Nakagawara A, Yamashiro DJ, et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neuro-Oncol 1997;31(1–2):49–55.

    CAS  Google Scholar 

  26. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334(4):225–230.

    PubMed  CAS  Google Scholar 

  27. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340(25):1954–1961.

    PubMed  CAS  Google Scholar 

  28. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8(3):278–292.

    PubMed  Google Scholar 

  29. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466–1477.

    PubMed  CAS  Google Scholar 

  30. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19(14):3397–3405.

    PubMed  CAS  Google Scholar 

  31. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199(3):743–750.

    PubMed  CAS  Google Scholar 

  32. Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 2004;29(2):86–90.

    PubMed  Google Scholar 

  33. Evans AE, D’Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children’s cancer study group A. Cancer (Phila) 1971;27(2):374–378.

    PubMed  CAS  Google Scholar 

  34. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224(4653):1121–1124.

    PubMed  CAS  Google Scholar 

  35. Cohn SL, Rademaker AW, Salwen HR, et al. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 1990;136(5):1043–1052.

    PubMed  CAS  Google Scholar 

  36. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311(4):231–235.

    PubMed  CAS  Google Scholar 

  37. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 2000;18(9):1888–1899.

    PubMed  CAS  Google Scholar 

  38. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313(18):1111–1116.

    PubMed  CAS  Google Scholar 

  39. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73(2):405–416.

    PubMed  CAS  Google Scholar 

  40. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000;22(3):197–205.

    PubMed  CAS  Google Scholar 

  41. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol 2000;18(1):18–26.

    PubMed  CAS  Google Scholar 

  42. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341(16):1165–1173.

    PubMed  CAS  Google Scholar 

  43. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16(3):953–965.

    PubMed  CAS  Google Scholar 

  44. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18(13):2567–2575.

    PubMed  CAS  Google Scholar 

  45. Grupp SA, Stern JW, Bunin N, et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000;35(6):696–700.

    PubMed  CAS  Google Scholar 

  46. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002;20(9):2284–2292.

    PubMed  CAS  Google Scholar 

  47. Marcus KJ, Shamberger R, Litman H, et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003;25(12):934–940.

    PubMed  Google Scholar 

  48. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000;18(3):477–486.

    PubMed  CAS  Google Scholar 

  49. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience: a pediatric oncology group study. J Clin Oncol 1998;16(6):2007–2017.

    PubMed  CAS  Google Scholar 

  50. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998;22(7):669–674.

    PubMed  CAS  Google Scholar 

  51. Meadows AT, Tsunematsu Y. Late effects for treatment for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds). Neuroblastoma. Amsterdam: Elsevier, 2000:561–570.

    Google Scholar 

  52. Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993;21(3):172–181.

    PubMed  CAS  Google Scholar 

  53. Miller RW, Fraumeni JF Jr, Manning MD. Association of Wilms tumor with aniridia, hemihypertrophy and other congenital anomalies. N Engl J Med 1964;270:922–927.

    PubMed  CAS  Google Scholar 

  54. Drash A, Sherman F, Hartmann WH, Blizzard RM. A syndrome of pseudohermaphroditism, Wilms’ tumor, hypertension, and degenerative renal disease. J Pediatr 1970;76(4):585–593.

    PubMed  CAS  Google Scholar 

  55. Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol 2003;21(24):4579–4585.

    PubMed  Google Scholar 

  56. Porteus MH, Narkool P, Neuberg D, et al. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms’ tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2000;18(10):2026–2031.

    PubMed  CAS  Google Scholar 

  57. Coppes MJ, Williams BR. The molecular genetics of Wilms tumor. Cancer Invest 1994;12(1):57–65.

    PubMed  CAS  Google Scholar 

  58. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res 1994;54(9):2331–2333.

    PubMed  CAS  Google Scholar 

  59. Bonadio JF, Storer B, Norkool P, Farewell VT, Beckwith JB, D’Angio GJ. Anaplastic Wilms’ tumor: clinical and pathologic studies. J Clin Oncol 1985;3(4):513–520.

    PubMed  CAS  Google Scholar 

  60. Grundy P, Green DM, Coppes MJ, et al. Renal tumors. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:865–938.

    Google Scholar 

  61. Shurin SB, Gauderer MW, Dahms BB, Conrad WG. Fatal intraoperative pulmonary embolization of Wilms tumor. J Pediatr 1982;101(4):559–562.

    PubMed  CAS  Google Scholar 

  62. Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol 1998;1(1):79–84.

    PubMed  CAS  Google Scholar 

  63. Coppes MJ, Wolff JE, Ritchey ML. Wilms tumour: diagnosis and treatment. Paediatr Drugs 1999;1(4):251–262.

    PubMed  CAS  Google Scholar 

  64. Pritchard J, Imeson J, Barnes J, et al. Results of the United Kingdom Children’s Cancer Study Group first Wilms’ Tumor Study. J Clin Oncol 1995;13(1):124–133.

    PubMed  CAS  Google Scholar 

  65. D’Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms’ tumor: results of the national Wilms’ tumor study. Cancer (Phila) 1976;38(2):633–646.

    PubMed  CAS  Google Scholar 

  66. D’Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms’ tumor: results of the Second National Wilms’ Tumor Study. Cancer (Phila) 1981;47(9):2302–2311.

    PubMed  CAS  Google Scholar 

  67. D’Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer (Phila) 1989;64(2):349–360.

    PubMed  CAS  Google Scholar 

  68. Green DM, Breslow NE, D’Angio GJ. The treatment of children with unilateral Wilms’ tumor. J Clin Oncol 1993;11(6):1009–1010.

    PubMed  CAS  Google Scholar 

  69. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 2001;19(17):3719–3724.

    PubMed  CAS  Google Scholar 

  70. Green DM. The treatment of stages I–IV favorable histology Wilms’ tumor. J Clin Oncol 2004;22(8):1366–1372.

    PubMed  Google Scholar 

  71. Grundy RG, Hutton C, Middleton H, et al. Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children’s Cancer Study Group (UKCCSG) study. Pediatr Blood Cancer 2004;42(4):311–319.

    PubMed  CAS  Google Scholar 

  72. Tournade MF, Com-Nougue C, Voute PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms’ tumor. J Clin Oncol 1993;11(6):1014–1023.

    PubMed  CAS  Google Scholar 

  73. Green DM. Wilms’ tumour. Eur J Cancer 1997;33(3):409–418; discussion 419–420.

    PubMed  CAS  Google Scholar 

  74. Cooper CS, Jaffe WI, Huff DS, et al. The role of renal salvage procedures for bilateral Wilms tumor: a 15-year review. J Urol 2000;163(1):265–268.

    PubMed  CAS  Google Scholar 

  75. Kumar R, Fitzgerald R, Breatnach F. Conservative surgical management of bilateral Wilms tumor: results of the United Kingdom Children’s Cancer Study Group. J Urol 1998;160(4):1450–1453.

    PubMed  CAS  Google Scholar 

  76. D’Angio GJ. Pre-or post-operative treatment for Wilms tumor? Who, what, when, where, how, why—and which. Med Pediatr Oncol 2003;41(6):545–549.

    PubMed  Google Scholar 

  77. Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms’ tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983;1(10):604–609.

    PubMed  CAS  Google Scholar 

  78. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol 2001;19(2):488–500.

    PubMed  CAS  Google Scholar 

  79. Grundy P, Breslow N, Green DM, Sharples K, Evans A, D’Angio GJ. Prognostic factors for children with recurrent Wilms’ tumor: results from the Second and Third National Wilms’ Tumor Study. J Clin Oncol 1989;7(5):638–647.

    PubMed  CAS  Google Scholar 

  80. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms’ tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22(1):11–14.

    PubMed  CAS  Google Scholar 

  81. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998;16(10):3295–3301.

    PubMed  CAS  Google Scholar 

  82. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms’ tumor patients: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol 1996;26(2):75–80.

    PubMed  CAS  Google Scholar 

  83. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac function in Wilms’ tumor survivors. J Clin Oncol 1995;13(7):1546–1556.

    PubMed  CAS  Google Scholar 

  84. Green DM, Donckerwolcke R, Evans AE, D’Angio GJ. Late effects of treatment for Wilms tumor. Hematol Oncol Clin N Am 1995;9(6):1317–1327.

    CAS  Google Scholar 

  85. Breslow NE, Takashima JR, Whitton JA, Moksness J, D’Angio GJ, Green DM. Second malignant neoplasms following treatment for Wilm’s tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1995;13(8):1851–1859.

    PubMed  CAS  Google Scholar 

  86. Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 2000;24(1):4–18.

    PubMed  CAS  Google Scholar 

  87. Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D’Angio GJ. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1994;12(10):2132–2137.

    PubMed  CAS  Google Scholar 

  88. Palmer NF, Sutow W. Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms’ Tumor Study Group. Med Pediatr Oncol 1983;11(4):242–245.

    PubMed  CAS  Google Scholar 

  89. Amar AM, Tomlinson G, Green DM, Breslow NE, de Alarcon PA. Clinical presentation of rhabdoid tumors of the kidney. J Pediatr Hematol Oncol 2001;23(2):105–108.

    PubMed  CAS  Google Scholar 

  90. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer (Phila) 1978;41(5):1937–1948.

    PubMed  CAS  Google Scholar 

  91. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (Lond) 1998;394(6689):203–206.

    PubMed  CAS  Google Scholar 

  92. Vujanic GM, Sandstedt B, Harms D, Boccon-Gibod L, Delemarre JF. Rhabdoid tumour of the kidney: a clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file. Histopathology (Oxf) 1996;28(4):333–340.

    PubMed  CAS  Google Scholar 

  93. Wagner L, Hill DA, Fuller C, et al. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 2002;24(5):385–388.

    PubMed  Google Scholar 

  94. Tomlinson GE, Nisen PD, Timmons CF, Schneider NR. Cytogenetics of a renal cell carcinoma in a 17-month-old child. Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet 1991;57(1):11–17.

    PubMed  CAS  Google Scholar 

  95. Tonk V, Wilson KS, Timmons CF, Schneider NR, Tomlinson GE. Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet Cytogenet 1995;81(1):72–75.

    PubMed  CAS  Google Scholar 

  96. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19(1):1–11.

    PubMed  Google Scholar 

  97. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145(1):1–30.

    PubMed  CAS  Google Scholar 

  98. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop 2002;397:40–52.

    PubMed  Google Scholar 

  99. Patino-Garcia A, Pineiro ES, Diez MZ, Iturriagagoitia LG, Klussmann FA, Ariznabarreta LS. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol 2003;25(5):362–367.

    PubMed  Google Scholar 

  100. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992;52(9):2419–2423.

    PubMed  CAS  Google Scholar 

  101. Tarkkanen M, Karhu R, Kallioniemi A, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995;55(6):1334–1338.

    PubMed  CAS  Google Scholar 

  102. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341(5):342–352.

    PubMed  CAS  Google Scholar 

  103. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11(3):449–453.

    PubMed  CAS  Google Scholar 

  104. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21(10):2011–2018.

    PubMed  Google Scholar 

  105. Simon R. Clinical prognostic factors in osteosarcoma. Cancer Treat Rep 1978;62(2):193–197.

    PubMed  CAS  Google Scholar 

  106. Look AT, Douglass EC, Meyer WH. Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity. N Engl J Med 1988;318(24):1567–1572.

    PubMed  CAS  Google Scholar 

  107. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 1996;14(2):467–472.

    PubMed  CAS  Google Scholar 

  108. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17(9):2781–2788.

    PubMed  CAS  Google Scholar 

  109. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16(7):2452–2458.

    PubMed  CAS  Google Scholar 

  110. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer (Phila) 1992;69(3):698–708.

    PubMed  CAS  Google Scholar 

  111. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972;4(5):482–510.

    PubMed  CAS  Google Scholar 

  112. Prindull G, Willert HG, Notter G. Local therapy of rhabdomyosarcoma, osteosarcoma and Ewing’s sarcoma of children and adolescents. Eur J Pediatr 1985;144(2):120–124.

    PubMed  CAS  Google Scholar 

  113. Goorin AM, Abelson HT, Frei E III. Osteosarcoma: fifteen years later. N Engl J Med 1985;313(26):1637–1643.

    PubMed  CAS  Google Scholar 

  114. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995;24(2):87–92.

    PubMed  CAS  Google Scholar 

  115. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastic Ewing’s sarcoma of primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group Study. J Clin Oncol 2004;22(14):2873–2876.

    PubMed  CAS  Google Scholar 

  116. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21(8):1574–1580.

    PubMed  CAS  Google Scholar 

  117. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14(7):1126–1134.

    PubMed  CAS  Google Scholar 

  118. Janinis J, McTiernan A, Driver D, et al. A pilot study of shortcourse intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. Ann Oncol 2002;13(12):1935–1944.

    PubMed  CAS  Google Scholar 

  119. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20(2):426–433.

    PubMed  CAS  Google Scholar 

  120. Weis LD. The success of limb-salvage surgery in the adolescent patient with osteogenic sarcoma. Adolesc Med 1999;10(3):451–458, xii.

    PubMed  CAS  Google Scholar 

  121. Bacci G, Ruggieri P, Bertoni F, et al. Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol Rep 2000;7(5):1129–1133.

    PubMed  CAS  Google Scholar 

  122. Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand 2003;74(4):449–454.

    PubMed  Google Scholar 

  123. Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop 1999 (358):83–89.

    PubMed  Google Scholar 

  124. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994;76(5):649–656.

    PubMed  CAS  Google Scholar 

  125. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer (Phila) 2003;98(11):2447–2456.

    PubMed  Google Scholar 

  126. Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 2003;39(14):2050–2057.

    PubMed  CAS  Google Scholar 

  127. Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch Surg 1989;124(1):122–126.

    PubMed  CAS  Google Scholar 

  128. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21(4):710–715.

    PubMed  Google Scholar 

  129. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332(26):1738–1743.

    PubMed  CAS  Google Scholar 

  130. Maygarden SJ, Askin FB, Siegal GP, et al. Ewing sarcoma of bone in infants and toddlers. A clinicopathologic report from the Intergroup Ewing’s Study. Cancer (Phila) 1993;71(6):2109–2118.

    PubMed  CAS  Google Scholar 

  131. Hartley AL, Birch JM, Blair V, Teare MD, Marsden HB, Harris M. Cancer incidence in the families of children with Ewing’s tumor. J Natl Cancer Inst 1991;83(13):955–956.

    PubMed  CAS  Google Scholar 

  132. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993;53(3):371–376.

    PubMed  CAS  Google Scholar 

  133. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 1998;16(4):1248–1255.

    PubMed  Google Scholar 

  134. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82(5):667–674.

    PubMed  CAS  Google Scholar 

  135. Grier HE. The Ewing family of tumors. Ewing’s sarcoma and primitive neuroectodermal tumors. Pediatr Clin N Am 1997;44(4):991–1004.

    CAS  Google Scholar 

  136. Cangir A, Vietti TJ, Gehan EA, et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer (Phila) 1990;66(5):887–893.

    PubMed  CAS  Google Scholar 

  137. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 2000;18(17):3108–3114.

    PubMed  CAS  Google Scholar 

  138. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9(3):275–281.

    PubMed  CAS  Google Scholar 

  139. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003;21(1):85–91.

    PubMed  Google Scholar 

  140. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer (Phila) 1988;61(1):23–32.

    PubMed  CAS  Google Scholar 

  141. Hayes FA, Thompson EI, Meyer WH, et al. Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol 1989;7(2):208–213.

    PubMed  CAS  Google Scholar 

  142. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997;33(7):1061–1069.

    PubMed  CAS  Google Scholar 

  143. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348(8):694–701.

    PubMed  CAS  Google Scholar 

  144. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998;16(11):3628–3633.

    PubMed  CAS  Google Scholar 

  145. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 2001;19(6):1818–1829.

    PubMed  CAS  Google Scholar 

  146. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 1997;15(4):1553–1559.

    PubMed  CAS  Google Scholar 

  147. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000;18(1):4–11.

    PubMed  CAS  Google Scholar 

  148. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8(10):1664–1674.

    PubMed  Google Scholar 

  149. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990;8(9):1514–1524.

    PubMed  Google Scholar 

  150. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 1995;13(11):2796–2804.

    PubMed  CAS  Google Scholar 

  151. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 1999;17(1):180–190.

    PubMed  CAS  Google Scholar 

  152. Bacci G, Toni A, Avella M, et al. Long-term results in 144 localized Ewing’s sarcoma patients treated with combined therapy. Cancer (Phila) 1989;63(8):1477–1486.

    PubMed  CAS  Google Scholar 

  153. Barbieri E, Emiliani E, Zini G, et al. Combined therapy of localized Ewing’s sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990;19(5):1165–1170.

    PubMed  CAS  Google Scholar 

  154. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer (Phila) 1999;86(3):421–428.

    PubMed  CAS  Google Scholar 

  155. Shankar AG, Pinkerton CR, Atra A, et al. Local therapy and other factors influencing site of relapse in patients with localised Ewing’s sarcoma. United Kingdom Children’s Cancer Study Group (UKCCSG). Eur J Cancer 1999;35(12):1698–1704.

    PubMed  CAS  Google Scholar 

  156. Hoffmann C, Ahrens S, Dunst J, et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer (Phila) 1999;85(4):869–877.

    PubMed  CAS  Google Scholar 

  157. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001;19(3):870–880.

    PubMed  CAS  Google Scholar 

  158. Yaniv I, Cohen IJ, Stein J, et al. Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer 2004;42(5):404–409.

    PubMed  CAS  Google Scholar 

  159. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979–1999. Cancer (Phila) 2002;94(2):561–569.

    PubMed  Google Scholar 

  160. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40(3):141–147.

    PubMed  CAS  Google Scholar 

  161. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19(15):3463–3469.

    PubMed  CAS  Google Scholar 

  162. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998;16(9):3016–3020.

    PubMed  CAS  Google Scholar 

  163. Novakovic B, Fears TR, Horowitz ME, Tucker MA, Wexler LH. Late effects of therapy in survivors of Ewing’s sarcoma family tumors. J Pediatr Hematol Oncol 1997;19(3):220–225.

    PubMed  CAS  Google Scholar 

  164. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969;43(6):1365–1373.

    PubMed  CAS  Google Scholar 

  165. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95(4):1606–1611.

    PubMed  CAS  Google Scholar 

  166. Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004;144(5):666–668.

    PubMed  Google Scholar 

  167. Sublett JE, Jeon IS, Shapiro DN. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene 1995;11(3):545–552.

    PubMed  CAS  Google Scholar 

  168. Scrable H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1989;1(1):23–35.

    PubMed  CAS  Google Scholar 

  169. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer (Phila) 1988;61(2):209–220.

    PubMed  CAS  Google Scholar 

  170. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer (Phila) 1993;71(5):1904–1922.

    PubMed  CAS  Google Scholar 

  171. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13(3):610–630.

    PubMed  CAS  Google Scholar 

  172. Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990;8(3):443–452.

    PubMed  CAS  Google Scholar 

  173. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 2004;42(1):64–73.

    PubMed  CAS  Google Scholar 

  174. Hays DM, Raney RB, Crist WM, et al. Secondary surgical procedures to evaluate primary tumor status in patients with chemotherapy-responsive stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg 1990;25(10):1100–1105.

    PubMed  CAS  Google Scholar 

  175. Godzinski J, Flamant F, Rey A, Praquin MT, Martelli H. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994;22(1):22–26.

    PubMed  CAS  Google Scholar 

  176. Wilbur JR. Combination chemotherapy for embryonal rhabdomyosarcoma. Cancer Chemother Rep 1974;58(2):281–284.

    PubMed  CAS  Google Scholar 

  177. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000;35(5):468–474.

    PubMed  CAS  Google Scholar 

  178. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17(6):1815–1824.

    PubMed  CAS  Google Scholar 

  179. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21(1):78–84.

    PubMed  Google Scholar 

  180. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17(9):2796–2803.

    PubMed  CAS  Google Scholar 

  181. Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extra-osseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998;16(5):1697–1706.

    PubMed  CAS  Google Scholar 

  182. Walterhouse DO, Hoover ML, Marymont MA, Kletzel M. High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children’s Memorial Hospital. Med Pediatr Oncol 1999;32(2):88–92.

    PubMed  CAS  Google Scholar 

  183. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999;17(11):3487–3493.

    PubMed  CAS  Google Scholar 

  184. Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003;38(3):560–566.

    PubMed  Google Scholar 

  185. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998;132 (3 pt 1):398–400.

    PubMed  CAS  Google Scholar 

  186. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998;79(4):274–278.

    PubMed  CAS  Google Scholar 

  187. Clericuzio CL, Chen E, McNeil DE, et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr 2003;143(2):270–272.

    PubMed  Google Scholar 

  188. Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance? J Pediatr 1997;130(4):557–560.

    PubMed  CAS  Google Scholar 

  189. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist 2000;5(6):445–453.

    PubMed  CAS  Google Scholar 

  190. Reynolds P, Urayama KY, Von Behren J, Feusner J. Birth characteristics and hepatoblastoma risk in young children. Cancer (Phila) 2004;100(5):1070–1076.

    PubMed  Google Scholar 

  191. Ribons LA, Slovis TL. Hepatoblastoma and birth weight. J Pediatr 1998;132(4):750.

    PubMed  CAS  Google Scholar 

  192. Feusner J, Buckley J, Robison L, Ross J, Van Tornout J. Prematurity and hepatoblastoma: more than just an association? J Pediatr 1998;133(4):585–586.

    PubMed  CAS  Google Scholar 

  193. Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC. Where do we stand with hepatoblastoma? A review. Cancer (Phila) 2003;98(4):668–678.

    PubMed  CAS  Google Scholar 

  194. Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994;54(19):5041–5044.

    PubMed  CAS  Google Scholar 

  195. Zatkova A, Rouillard JM, Hartmann W, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer (Phila) 2004;39(2):126–137.

    PubMed  CAS  Google Scholar 

  196. Saxena R, Leake JL, Shafford EA, et al. Chemotherapy effects on hepatoblastoma. A histological study. Am J Surg Pathol 1993;17(12):1266–1271.

    PubMed  CAS  Google Scholar 

  197. Lack EE, Neave C, Vawter GF. Hepatoblastoma. A clinical and pathologic study of 54 cases. Am J Surg Pathol 1982;6(8):693–705.

    PubMed  CAS  Google Scholar 

  198. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol 1991;9(12):2167–2176.

    PubMed  CAS  Google Scholar 

  199. Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer (Phila) 2001;92(12):3130–3134.

    PubMed  CAS  Google Scholar 

  200. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 1997;15(3):1190–1197.

    PubMed  Google Scholar 

  201. Stringer MD, Hennayake S, Howard ER, et al. Improved outcome for children with hepatoblastoma. Br J Surg 1995;82(3):386–391.

    PubMed  CAS  Google Scholar 

  202. Seo T, Ando H, Watanabe Y, et al. Treatment of hepatoblastoma: less extensive hepatectomy after effective preoperative chemotherapy with cisplatin and adriamycin. Surgery (St. Louis) 1998;123(4):407–414.

    PubMed  CAS  Google Scholar 

  203. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma: results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000;36(11):1418–1425.

    PubMed  CAS  Google Scholar 

  204. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer (Phila) 2002;94(4):1111–1120.

    PubMed  Google Scholar 

  205. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000;1:94–100.

    PubMed  CAS  Google Scholar 

  206. Carceller A, Blanchard H, Champagne J, St-Vil D, Bensoussan AL. Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma. J Pediatr Surg 2001;36(5):755–759.

    PubMed  CAS  Google Scholar 

  207. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18(14):2665–2675.

    PubMed  CAS  Google Scholar 

  208. Fuchs J, Rydzynski J, Hecker H, et al. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma: a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94. Eur J Pediatr Surg 2002;12(4):255–261.

    PubMed  CAS  Google Scholar 

  209. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer (Phila) 2002;95(1):172–182.

    PubMed  Google Scholar 

  210. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002;37(6):851–856.

    PubMed  CAS  Google Scholar 

  211. Srinivasan P, McCall J, Pritchard J, et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation 2002;74(5):652–655.

    PubMed  CAS  Google Scholar 

  212. Pimpalwar AP, Sharif K, Ramani P, et al. Strategy for hepatoblastoma management: transplant versus nontransplant surgery. J Pediatr Surg 2002;37(2):240–245.

    PubMed  CAS  Google Scholar 

  213. Molmenti EP, Wilkinson K, Molmenti H, et al. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. Am J Transplant 2002;2(6):535–538.

    PubMed  Google Scholar 

  214. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 2002;20(16):3438–3444.

    PubMed  Google Scholar 

  215. Feusner JH, Krailo MD, Haas JE, Campbell JR, Lloyd DA, Ablin AR. Treatment of pulmonary metastases of initial stage I hepatoblastoma in childhood. Report from the Childrens Cancer Group. Cancer (Phila) 1993;71(3):859–864.

    PubMed  CAS  Google Scholar 

  216. Matsunaga T, Sasaki F, Ohira M, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 2003;19(3):142–146.

    PubMed  Google Scholar 

  217. Nishimura S, Sato T, Fujita N, et al. High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 2002;44(3):300–305.

    PubMed  CAS  Google Scholar 

  218. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002;20(12):2798–2804.

    PubMed  CAS  Google Scholar 

  219. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 2002;20(12):2789–2797.

    PubMed  Google Scholar 

  220. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990;108(1):128–132.

    PubMed  CAS  Google Scholar 

  221. Rubenfeld M, Abramson DH, Ellsworth RM, Kitchin FD. Unilateral vs. bilateral retinoblastoma. Correlations between age at diagnosis and stage of ocular disease. Ophthalmology 1986;93(8):1016–1019.

    PubMed  CAS  Google Scholar 

  222. Paulino AC. Trilateral retinoblastoma: is the location of the intracranial tumor important? Cancer (Phila) 1999;86(1):135–141.

    PubMed  CAS  Google Scholar 

  223. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68(4):820–823.

    PubMed  Google Scholar 

  224. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (Lond) 1986;323(6089):643–646.

    PubMed  CAS  Google Scholar 

  225. Shields J. Retinoblastoma: clinical, and pathological features. In: Intraocular Tumors: A Text and Atlas. Philadelphia: Saunders, 1992:305–332.

    Google Scholar 

  226. Tajima Y, Nakajima T, Sugano I, Nagao K, Minoda K, Kondo Y. Cytodiagnostic clues to primary retinoblastoma based on cytologic and histologic correlates of 39 enucleated eyes. Acta Cytol 1994;38(2):151–157.

    PubMed  CAS  Google Scholar 

  227. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics 2003;112 (6 pt 1):1248–1255.

    PubMed  Google Scholar 

  228. Balmer A, Gailloud C, Munier F, Uffer S, Guex-Crosier Y. Retinoblastoma. Unusual warning and clinical signs. Ophthalmic Paediatr Genet 1993;14(1):33–38.

    PubMed  CAS  Google Scholar 

  229. McLean IW, Burnier M, Zimmerman L, Jakobiec F. Tumors of the retina. In: McLean IW, Burnier M, Zimmerman L (eds). Atlas of Tumor Pathology: Tumors of the Eye and Ocular Adnexa. Washington, DC: Armed Forces Institute of Pathology, 1994:100–135.

    Google Scholar 

  230. Char DH, Hedges TR III, Norman D. Retinoblastoma. CT diagnosis. Ophthalmology 1984;91(11):1347–1350.

    PubMed  CAS  Google Scholar 

  231. Howard GM, Ellsworth RM. Differential diagnosis of retinoblastoma. A statistical survey of 500 children. I. Relative frequency of the lesions which simulate retinoblastoma. Am J Ophthalmol 1965;60(4):610–618.

    PubMed  CAS  Google Scholar 

  232. Pratt CB, Fontanesi J, Lu X, Parham DM, Elfervig J, Meyer D. Proposal for a new staging scheme for intraocular and extraocular retinoblastoma based on an analysis of 103 globes. Oncologist 1997;2(1):1–5.

    PubMed  Google Scholar 

  233. De Sutter E, Hoepping W, Zeller G. Comparison between different retinoblastoma classifications. Bull Soc Belg Ophtalmol 1993;248:19–22.

    Google Scholar 

  234. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer (Phila) 1996;77(6):1206–1213.

    PubMed  CAS  Google Scholar 

  235. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 1987;94(4):371–377.

    PubMed  CAS  Google Scholar 

  236. Merchant TE, Gould CJ, Hilton NE, et al. Ocular preservation after 36 Gy external beam radiation therapy for retinoblastoma. J Pediatr Hematol Oncol 2002;24(4):246–249.

    PubMed  Google Scholar 

  237. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114(11):1321–1328.

    PubMed  CAS  Google Scholar 

  238. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000;18(15):2881–2887.

    PubMed  CAS  Google Scholar 

  239. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 2002;38(6):411–415.

    PubMed  Google Scholar 

  240. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18(1):12–17.

    PubMed  CAS  Google Scholar 

  241. Lumbroso L, Doz F, Urbieta M, et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology 2002;109(6):1130–1136.

    PubMed  Google Scholar 

  242. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997;104(12):2101–2111.

    PubMed  CAS  Google Scholar 

  243. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120(12):1653–1658.

    PubMed  Google Scholar 

  244. Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001;108(11):2106–2114; discussion 2114–2115.

    PubMed  CAS  Google Scholar 

  245. Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs. external beam radiotherapy. Arch Ophthalmol 2003;121(7):979–984.

    PubMed  Google Scholar 

  246. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133(5):657–664.

    PubMed  Google Scholar 

  247. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002;120(7):923–931.

    PubMed  Google Scholar 

  248. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology 2003;110(6):1237–1240.

    PubMed  Google Scholar 

  249. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997;33(14):2368–2375.

    PubMed  CAS  Google Scholar 

  250. Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. Approaches to treatment for extraocular retinoblastoma: Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004;26(1):31–34.

    PubMed  Google Scholar 

  251. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer (Phila) 2000;89(10):2117–2121.

    PubMed  CAS  Google Scholar 

  252. Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001;119(9):1269–1272.

    PubMed  CAS  Google Scholar 

  253. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53(5):661–671.

    PubMed  CAS  Google Scholar 

  254. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85(14):1121–1128.

    PubMed  CAS  Google Scholar 

  255. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278(15):1262–1267.

    PubMed  CAS  Google Scholar 

  256. Rescorla FJ, Breitfeld PP. Pediatric germ cell tumors. Curr Probl Cancer 1999;23(6):257–303.

    PubMed  CAS  Google Scholar 

  257. Lau YF. Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am J Hum Genet 1999;64(4):921–927.

    PubMed  CAS  Google Scholar 

  258. Lau YF, Lau HW, Komuves LG. Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. Cytogenet Genome Res 2003;101(3–4):250–260.

    PubMed  CAS  Google Scholar 

  259. Fonkalsrud EW. The undescended testis. Curr Probl Surg 1978;15(3):1–56.

    PubMed  CAS  Google Scholar 

  260. Fonkalsrud EW. Current management of the undescended testis. Semin Pediatr Surg 1996;5(1):2–7.

    PubMed  CAS  Google Scholar 

  261. Jones BJ, Thornhill JA, O’Donnell B, et al. Influence of prior orchiopexy on stage and prognosis of testicular cancer. Eur Urol 1991;19(3):201–203.

    PubMed  CAS  Google Scholar 

  262. Bussey KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences: a Children’s Cancer Group study. Genes Chromosomes Cancer 1999;25(2):134–146.

    PubMed  CAS  Google Scholar 

  263. Cushing B, Perlman E, Marina N, Castleberry R. Germ Cell Tumors. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 4th ed. Lippincott Williams & Wilkins, 2002:1091–1113.

    Google Scholar 

  264. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol 2001;19(9):2534–2541.

    PubMed  CAS  Google Scholar 

  265. Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 1981;15(1):50–52.

    PubMed  CAS  Google Scholar 

  266. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children’s Cancer Group Intergroup Study. J Clin Oncol 1999;17(7):2137–2143.

    PubMed  CAS  Google Scholar 

  267. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children’s cancer group. Am J Obstet Gynecol 1999;181(2):258–353.

    Google Scholar 

  268. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study—Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol 2004;22(13):2691–2700.

    PubMed  CAS  Google Scholar 

  269. Williams S, Blessing J, Slayton R. Ovarian germ cell tumors: adjuvant trials of the gynecologic oncology group. In: Salma S (ed). Proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer 1990:501–503.

    Google Scholar 

  270. Einhorn LH. Chemotherapy of disseminated germ cell tumors. Cancer (Phila) 1987;60(suppl 31):570–573.

    PubMed  CAS  Google Scholar 

  271. Schlatter M, Rescorla F, Giller R, et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children’s Cancer Group/Pediatric Oncology Group. J Pediatr Surg 2003;38(3):319–324; discussion 324.

    PubMed  Google Scholar 

  272. Gobel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11(3):263–271.

    PubMed  CAS  Google Scholar 

  273. Baranzelli MC, Bouffet E, Quintana E, Portas M, Thyss A, Patte C. Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer 2000;36(3):376–383.

    PubMed  CAS  Google Scholar 

  274. Baranzelli MC, Flamant F, De Lumley L, Le Gall E, Lejars O. Treatment of non-metastatic, non-seminomatous malignant germ-cell tumours in childhood: experience of the “Societe Francaise d’Oncologie Pediatrique” MGCT 1985–1989 study. Med Pediatr Oncol 1993;21(6):395–401.

    PubMed  CAS  Google Scholar 

  275. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997;33(12):2121–2125.

    PubMed  CAS  Google Scholar 

  276. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998;16(4):1256–1264.

    PubMed  CAS  Google Scholar 

  277. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002;24(8):613–621.

    PubMed  Google Scholar 

  278. Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995;17(3):254–259.

    PubMed  CAS  Google Scholar 

  279. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003;25(11):845–853.

    PubMed  Google Scholar 

  280. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39(4):488–494.

    PubMed  CAS  Google Scholar 

  281. Granowetter L, Womer R, Devidas M. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing’s sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children’s Cancer Group phase III trial. Med Pediatr Oncol 2001;37:172.

    Google Scholar 

  282. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003;21(16):3072–3078.

    PubMed  CAS  Google Scholar 

  283. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 2001;19(11):2812–2820.

    PubMed  CAS  Google Scholar 

  284. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091–3102.

    PubMed  CAS  Google Scholar 

  285. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma: a report from the IRSG. Int J Radiat Oncol Biol Phys 2001;51(3):718–728.

    PubMed  CAS  Google Scholar 

  286. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol 1993;11(1):96–99.

    PubMed  CAS  Google Scholar 

  287. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach. Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18(22):3819–3828.

    PubMed  CAS  Google Scholar 

  288. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2. Eur J Cancer 2004;40(3):411–421.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology-Oncology, Case Western University, Cleveland, OH, USA

    Crawford J. Strunk MD (Fellow)

  2. Division of Pediatric Hematology and Oncology, Rainbow Babies and Children’s Hospital, Cleveland, OH, USA

    Crawford J. Strunk MD (Fellow) & Sarah W. Alexander MD (Assistant Professor)

  3. Department of Pediatrics, Case Western University, Cleveland, OH, USA

    Sarah W. Alexander MD (Assistant Professor)

Authors
  1. Crawford J. Strunk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah W. Alexander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Strunk, C.J., Alexander, S.W. (2006). Solid Tumors of Childhood. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_62

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_62

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation